- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Syngene, HiMedia collaborate to launch COVID-19 test kits under brand name ELISafe 19 in India
As part of the collaboration, Syngene will initiate tech-transfer of the kits to HiMedia for developing the prototypes for submission to CDSCO for approval.
Bengaluru: Syngene International Ltd., an integrated research and development services company, has entered into a collaboration with HiMedia Laboratories, a bioscience company with expertise in media manufacturing and diagnostics for over 45 years, to manufacture and distribute its ELISA kits. HiMedia will manufacture the kits at its facility in Mumbai and distribute it across India.
As part of the collaboration, Syngene will initiate tech-transfer of the kits to HiMedia for developing the prototypes for submission to CDSCO for approval. HiMedia will launch the kits in two weeks after receiving the approval and market it under its brand name ELISafe 19.
Syngene has indigenously developed an anti-COV-2 IgG ELISA (Enzyme-Linked Immunosorbent Assay) at its research facility in Bengaluru. This advanced highly reliable test identifies the presence of SARS-COV-2 antibodies in blood samples and confirms if a patient has been exposed to the coronavirus. It has the capacity to test samples together in a single run and generates results within 3 hours.
Commenting on the collaboration, Dr Mahesh Bhalgat, Chief Operating Officer, Syngene International Ltd., said, "At a time when the number of COVID-19 cases is increasing at an alarming rate across the country, there is an urgent need to make available reliable testing kits using advanced technology to test patients and identify positive cases. To fill this gap, Syngene, with its expertise across diverse scientific domains, has developed an ELISA kit that allows higher throughput and generates faster results. We are happy to tie-up with HiMedia who will make the kits available at a large scale to significantly increase serological testing in India."
distributing their ELISA kits. This partnership brings together our mutual expertise in research and manufacturing and will further strengthen our fight against the COVID19 pandemic."
Also Read: COVID-19 Testing Kits: Mylab Joins Hands With Syngene International
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751